



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

November 29, 2004

David G. Adams
Venable, LLP
575 F Street, NW
Washington, DC 20004-1601

Dear Mr. Adams:

This is a correction to a November 22, 2004 letter. The correction is being made to the address.

Your petition, on behalf IVAX Pharmaceuticals, Inc. requesting the Food and Drug Administration to confirm that IVAX is 180-Day Exclusivity for Ipratropium Bromide and Albuterol Sulfate Inhalation solution, was received by this office on 11/22/2004. It was assigned docket number 2004P-0520/CP1 and it was filed on 11/22/2004. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

/s/

Jennie C. Butler, Director
Division of Dockets Management
Office of Management Programs
Office of Management